Evaxion announce 2026 financial calendar

Rhea-AI Summary

Evaxion (NASDAQ: EVAX) announced its 2026 financial calendar on November 12, 2025. Key scheduled dates include:

• March 5, 2026 – Business update and full year 2025 financial results
• April 16, 2026 – Annual General Meeting
• May 7, 2026 – Business update and Q1 2026 financial results
• August 20, 2026 – Business update and Q2 2026 financial results
• November 19, 2026 – Business update and Q3 2026 financial results

The company said the full calendar is available on its website and provided investor relations contact details.

COPENHAGEN, Denmark, November 12, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its financial calendar for 2026 as summarized below:

March 5, 2026: Business update and full year 2025 financial results

April 16, 2026: Annual General Meeting

May 7, 2026: Business update and first quarter 2026 financial results

August 20, 2026: Business update and second quarter 2026 financial results

November 19, 2026: Business update and third quarter 2026 financial results

The financial calendar can also be found on our website.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What dates did Evaxion (EVAX) set for its 2026 financial results?

Evaxion scheduled results on March 5, May 7, August 20, and November 19, 2026 for full-year 2025, Q1, Q2, and Q3 updates respectively.

When is Evaxion's (EVAX) 2026 Annual General Meeting?

The Annual General Meeting is set for April 16, 2026.

How can investors access Evaxion (EVAX) 2026 calendar details?

The financial calendar is available on Evaxion's website and via the investor relations contact provided by the company.

Who is the investor relations contact for Evaxion (EVAX)?

Investor relations contact listed is Mads Kronborg, Vice President, Investor Relations & Communication with the provided phone and email.

Which date will Evaxion (EVAX) report full year 2025 financial results?

Evaxion will report full year 2025 financial results on March 5, 2026.